Transgene SA
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillom… Read more
Transgene SA (TRGNF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 4.979x
Based on the latest financial reports, Transgene SA (TRGNF) has a cash flow conversion efficiency ratio of 4.979x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.95 Million) by net assets ($-3.60 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Transgene SA - Cash Flow Conversion Efficiency Trend (1997–2024)
This chart illustrates how Transgene SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Transgene SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Transgene SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Encounter Resources Limited
F:E6H
|
N/A |
|
Kitanotatsujin Corporation
PINK:KITAF
|
0.131x |
|
Rhom Bho Property Public Company Limited
BK:TITLE
|
-0.254x |
|
Rugvista Group AB
ST:RUG
|
0.124x |
|
ZenaTech Inc.
NASDAQ:ZENA
|
-0.168x |
|
THERMADOR GRPE INH.EO 4
F:T8DA
|
N/A |
|
Avjennings Ltd
AU:AVJ
|
0.025x |
|
A-Jin Industry Co Ltd
KQ:013310
|
-0.060x |
Annual Cash Flow Conversion Efficiency for Transgene SA (1997–2024)
The table below shows the annual cash flow conversion efficiency of Transgene SA from 1997 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $15.20 Million | $-23.55 Million | -1.549x | +30.26% |
| 2023-12-31 | $15.61 Million | $-34.67 Million | -2.221x | -313.91% |
| 2022-12-31 | $37.84 Million | $-20.30 Million | -0.537x | -12.89% |
| 2021-12-31 | $67.21 Million | $-31.94 Million | -0.475x | +16.91% |
| 2020-12-31 | $50.25 Million | $-28.74 Million | -0.572x | -67.66% |
| 2019-12-31 | $65.70 Million | $-22.41 Million | -0.341x | +55.88% |
| 2018-12-31 | $36.70 Million | $-28.38 Million | -0.773x | +38.59% |
| 2017-12-31 | $28.09 Million | $-35.37 Million | -1.259x | -74.35% |
| 2016-12-31 | $46.50 Million | $-33.59 Million | -0.722x | +57.54% |
| 2015-12-31 | $26.55 Million | $-45.15 Million | -1.701x | -125.29% |
| 2014-12-31 | $71.84 Million | $-54.24 Million | -0.755x | +14.82% |
| 2013-12-31 | $56.62 Million | $-50.19 Million | -0.886x | -72.06% |
| 2012-12-31 | $99.58 Million | $-51.29 Million | -0.515x | -64.95% |
| 2011-12-31 | $141.42 Million | $-44.16 Million | -0.312x | -130.02% |
| 2010-12-31 | $183.62 Million | $-24.93 Million | -0.136x | +50.28% |
| 2009-12-31 | $68.56 Million | $-18.72 Million | -0.273x | -10.00% |
| 2008-12-31 | $94.22 Million | $-23.39 Million | -0.248x | -1228.28% |
| 2007-12-31 | $110.94 Million | $-2.07 Million | -0.019x | +98.18% |
| 2006-12-31 | $18.98 Million | $-19.54 Million | -1.029x | +23.32% |
| 2004-12-31 | $14.23 Million | $-19.11 Million | -1.343x | -154.45% |
| 2003-12-31 | $34.52 Million | $-18.21 Million | -0.528x | -81.78% |
| 2002-12-31 | $55.21 Million | $-16.02 Million | -0.290x | -35.93% |
| 2001-12-31 | $73.63 Million | $-15.72 Million | -0.214x | +66.64% |
| 2000-12-31 | $34.79 Million | $-22.27 Million | -0.640x | -155.78% |
| 1999-12-31 | $55.48 Million | $-13.88 Million | -0.250x | +45.04% |
| 1998-12-31 | $73.49 Million | $-33.47 Million | -0.455x | +19.95% |
| 1997-12-31 | $20.68 Million | $-11.77 Million | -0.569x | -- |